Recombinant therapeutic proteins: Production platforms and challenges
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Since the approval of insulin in 1982, more than 120 recombinant drug substances have been approved and become available as extremely valuable therapeutic options. Exact copying of the most common human form is no longer a value per se, as challenges, primarily related to the pharmacokinetics of artificial recombinant drugs, can be overcome by diverging from the original. However, relatively minor changes in manufacturing or packaging may impact safety of therapeutic proteins. A major achievement is the development of recombinant proteins capable of entering a cell. Such drugs open up completely new opportunities by targeting intracellular mechanisms or by substituting intracellularly operating enzymes. Concerns that protein variants would cause an intolerable immune response turned out to be exaggerated. Although most recombinant drugs provoke some immune response, they are still well tolerated. This knowledge might result in a change in attitude towards antibody formation, i.e., neutralizing antibody activity (in vitro) may be overcome by dosing consistently on the basis of antibody titers and not only on body weight. As with other drugs, efficacy and safety of therapeutic proteins have to be demonstrated in clinical studies, and superiority over available products has to be proven instead of just claimed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Overview of N- and O-linked oligosaccharide structures found in various yeast species
Gemmill, T. R., & Trimble, R. B. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(98)00126-3 · Cited by 439 · cited 1×
“cerevisiae expresses Nglycosylation sites encoded by human genes, its glycosylation pattern is so different from that of humans [4] that concerns about whether such an “artificial” glycosylation of recombinant products would induce a severe immune response in humans were raised.”
Background
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Assessment of Recent Process Analytical Technology (PAT) Trends: A Multiauthor Review
Simon, L. L., Pataki, H., Marosi, G., Meemken, F., Hungerbühler, K., Baiker, A., Tummala, S., Glennon, B., Kuentz, M., Steele, G., et al. (2015) · Organic Process Research & Development · doi:10.1021/op500261y · Cited by 439
Kwon, H., Kim, M., Seo, Y., Moon, Y. S., Lee, H. J., Lee, K., & Lee, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.034 · Cited by 208
Grillberger, L., Kreil, T. R., Nasr, S., & Reiter, M. (2009) · Biotechnology Journal · doi:10.1002/biot.200800241 · Cited by 144
Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo)
Llop, E., Gutiérrez-Gallego, R., Segura, J., Mallorquí, J., & Pascual, J. A. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.08.027 · Cited by 79
“Although it is extremely difficult to establish the precise contribution of individual glycoforms to the overall activity, toxicity, and (in some cases) immunogenicity of these biopharmaceuticals, analysis of their glycosylation pattern is of utmost importance in attempting such understanding in addition to guaranteei…”
Background
Metadata
- Authors
- Dingermann, T.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2008-01
- Volume
- 3
- Issue
- 1
- Pages
- 90-97
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2044931811
- Cited by
- 162
- References
- 2
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.